Trial Profile
A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs LB 100 (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Lixte Biotechnology Holdings
- 04 Jan 2017 Results published in a Lixte Biotechnology Holdings media release.
- 04 Jan 2017 According to a Lixte Biotechnology Holdings media release, results published in Clinical Cancer Research.
- 28 Sep 2016 Status changed from active, no longer recruiting to completed.